AstraZeneca signs Alteogen deal worth up to $1.35B for subcutaneous cancer drugs despite Merck-Halozyme patent drama

AstraZeneca has signed two deals worth $1.35 billion with Alteogen to development subcutaneous versions of the British pharma’s cancer drugs despite a potential patent infringement risk.